Vectura Group PLC (LON:VEC) insider Andrew Derodra acquired 156 shares of Vectura Group PLC stock in a transaction on Wednesday, November 8th. The shares were purchased at an average cost of GBX 96 ($1.26) per share, with a total value of £149.76 ($196.97).

Andrew Derodra also recently made the following trade(s):

  • On Friday, October 6th, Andrew Derodra acquired 142 shares of Vectura Group PLC stock. The shares were purchased at an average cost of GBX 106 ($1.39) per share, with a total value of £150.52 ($197.97).
  • On Friday, September 8th, Andrew Derodra acquired 158 shares of Vectura Group PLC stock. The shares were purchased at an average cost of GBX 94 ($1.24) per share, with a total value of £148.52 ($195.34).
  • On Thursday, September 7th, Andrew Derodra acquired 82,000 shares of Vectura Group PLC stock. The shares were purchased at an average cost of GBX 90 ($1.18) per share, with a total value of £73,800 ($97,066.95).

Shares of Vectura Group PLC (VEC) opened at GBX 90.55 ($1.19) on Friday. Vectura Group PLC has a 12-month low of GBX 86.50 ($1.14) and a 12-month high of GBX 166.97 ($2.20).

COPYRIGHT VIOLATION WARNING: “Andrew Derodra Acquires 156 Shares of Vectura Group PLC (VEC) Stock” was first reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international copyright legislation. The legal version of this piece can be accessed at https://www.watchlistnews.com/andrew-derodra-acquires-156-shares-of-vectura-group-plc-vec-stock/1694545.html.

VEC has been the subject of several research reports. J P Morgan Chase & Co reduced their price objective on Vectura Group PLC from GBX 180 ($2.37) to GBX 175 ($2.30) and set an “overweight” rating for the company in a report on Friday. Numis Securities Ltd reissued a “buy” rating and set a GBX 205 ($2.70) price objective on shares of Vectura Group PLC in a report on Thursday, September 7th. Peel Hunt reaffirmed a “hold” rating on shares of Vectura Group PLC in a report on Thursday. Panmure Gordon reaffirmed a “buy” rating and issued a GBX 150 ($1.97) price target on shares of Vectura Group PLC in a report on Thursday. Finally, Shore Capital reaffirmed a “buy” rating on shares of Vectura Group PLC in a report on Wednesday, August 16th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of GBX 189.67 ($2.49).

About Vectura Group PLC

Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The Company’s products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) – LABA-LAMA; Seebri Breezhaler (EU and RoW) – LAMA; AirFluSal Forspiro (EU and RoW) – ICS-LABA; ADVATE (Global) – Antihaemophilic Factor (Recombinant); Adept (Global) – Icodextrin; Anoro Ellipta (Global) – LAMA-LABA; Relvar Ellipta/Breo Ellipta (Global) – ICS-LABA, and Incruse Ellipta (Global) – LAMA.

Insider Buying and Selling by Quarter for Vectura Group PLC (LON:VEC)

Receive News & Ratings for Vectura Group PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vectura Group PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.